Navigation Links
Neumedicines Receives Award of $14 Million from BARDA for Continued Development of HemaMax™ as a Medical Countermeasure to Acute Radiation Exposure
Date:8/14/2014

n that HemaMax™ is safe in healthy volunteers.”

“With BARDA’s continued funding, we are advancing HemaMax™ toward consideration for EUA, which, if granted, would allow for its use in the event of a radiological/nuclear emergency,” she added. “We believe HemaMax™ could have a significant impact in saving lives in such an event, and our team is committed to advancing HemaMax™ so that it may soon be a component of the United States’ arsenal in countering radiological/nuclear emergencies.”

Research and development of HemaMax™ for HSARS has been funded entirely with federal funds from the Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract Nos. HHSO1002000800060C and HHSO100201100037C.

“We are also focused on developing rHuIL-12 as an immunotherapy for cancer patients to be used in combination with various cancer treatments, including radiation, chemotherapies, and other immunotherapies. The promise of IL-12 as an immunotherapy is substantiated by the fact that the National Cancer Institute (NCI) and the Cancer Immunotherapy Trials Network (CITN) consider IL-12 a Priority Agent and rank it the top priority vaccine adjuvant and the third overall immunotherapy agent, only behind IL-15 and anti-PD-1,” Dr. Basile stated.

About HemaMax™:

HemaMax™ (rHuIL-12) holds considerable value and promise playing a central role in linking and regulating both innate (early nonspecific) and adaptive (late specific) immunity, while also playing a critical role in hematopoietic cell-to-cell signaling. In addition to HSARS, HemaMax™ is also being developed for various indications in oncology, including cutaneous T cell lymphoma (CTCL), acute myeloid leukemia (AML), melanoma, solid tumors, various immunotherapy applications, and hematopoietic support.

About Neumedicines Inc.:

Neumedicines I
'/>"/>

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Advanced Cell Diagnostics Receives ISO 13485:2003 Certification
2. Rebiotix Inc. Receives $25M for Series B Funding
3. Orexigen Receives CHMP Day 180 List of Outstanding Issues
4. UT Dallas professor receives Engineer of the Year award
5. Global Graphene Manufacturing Leader, Graphene Frontiers, Receives Series Seed B Funding To Assure Production Of The Next Generation Of Biological And Chemical Sensor Technology
6. Young Moscovite Researcher Receives this Years "Basel Declaration Award for Education in Animal Research"
7. ImQuest Pharmaceuticals Receives FDA Approval to Initiate Clinical Trials of a Vaginal Gel for the Prevention of HIV Transmission to Women
8. Worcester Polytechnic Institute Receives NIH Grant to Study Components of a Potentially Potent and Cost-Effective Malaria Treatment
9. RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders
10. Gordon Hunter’s ‘How Are You, Mother Earth?’ Receives Four Stars from Clarion Review
11. DiaVacss Immunotherapy Product for Treatment of Type 1 Diabetes Receives Orphan Drug Status Designation from the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2015)... SAN DIEGO , July 24, 2015 ... corporate and financial results for the second quarter 2015 ... the announcement, Orexigen will provide a business update and ... conference call at 8:00 a.m. Eastern Time (5:00 a.m. ... accessed by phone by calling (800) 447-0521 (domestic) or ...
(Date:7/24/2015)... , July 24, 2015 ... expected to reach USD 27.8 billion by 2022, growing ... 2022, according to a new study by Grand View ... methodologies is expected to result in significant reduction in ... to augment adoption and usage rates of next generation ...
(Date:7/24/2015)... ... July 24, 2015 , ... ... frozen sample management solution, indispensable to any modern scientific or pharmaceutical laboratory. ... a user-friendly interface. Users know precisely where a sample is located even ...
(Date:7/23/2015)... ... ... The health and wellness of brain tumor caregivers, often a spouse, parent, sibling ... American Brain Tumor Association presents interactive sessions that address shifting the mindset of caregivers ... Chicago. , “We have understood for a long-time now that caregivers and families ...
Breaking Biology Technology:Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 2Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 3Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 4Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 5RURO, Inc. Partners with Integrated Systems Engineering to Provide Comprehensive LIMS Software to Biobanks 2RURO, Inc. Partners with Integrated Systems Engineering to Provide Comprehensive LIMS Software to Biobanks 3RURO, Inc. Partners with Integrated Systems Engineering to Provide Comprehensive LIMS Software to Biobanks 4Reframing the Caregiver and Patient Mindset: Coping with the ‘New Normal’ 2Reframing the Caregiver and Patient Mindset: Coping with the ‘New Normal’ 3
... in Waikoloa, Hawaii, has just installed the trailblazing new ... their restaurants, brown grease waste into clear water - ... a cost-cutting and "green" service is a business smart ... GRS drastically reduces the need to pump and haul ...
... Inc. (Nasdaq: CEPH ) announced today that it ... million of common stock and $350 million in aggregate principal ... concurrent public offerings. Cephalon will grant the underwriters a ... an additional $45 million of common stock, with respect to ...
... present itself as one of the,world,s leading regenerative ... Under the "Breakthroughs in Regenerative Medicines,in Germany" banner, ... research results in the area of regenerative medicine ... framework conditions will be,introduced in a presentation in ...
Cached Biology Technology:Marriott Resort Magically Turns Brown Grease "Green" With The Cost-Cutting Hydrologix GRS 2Marriott Resort Magically Turns Brown Grease "Green" With The Cost-Cutting Hydrologix GRS 3Cephalon Announces Proposed Public Offering of Common Stock and Convertible Senior Subordinated Notes 2Cephalon Announces Proposed Public Offering of Common Stock and Convertible Senior Subordinated Notes 3Cephalon Announces Proposed Public Offering of Common Stock and Convertible Senior Subordinated Notes 4Cephalon Announces Proposed Public Offering of Common Stock and Convertible Senior Subordinated Notes 5BIO International Convention 2009: Research Location Germany Presents Potential in Regenerative Medicine 2
(Date:7/9/2015)... , July 07, 2015 ... the addition of the "Biometrics for Banking; ... 2015-2020" report to their offering. ... contributor to this growth and the forecast is ... in revenue for companies involved in delivering biometric ...
(Date:7/8/2015)... NEW YORK , July 8, 2015 /PRNewswire/ ... today announced BD & Guidepoint Mentor, a ... access to Guidepoint,s expert network services. ... cutting-edge technologies to improve healthcare delivery and outcomes and, ... each start-up entrepreneur will be able to directly engage ...
(Date:7/7/2015)... 2015  Based on its recent analysis of ... Credence ID, LLC with the 2015 Asia-Pacific ... Year Award. Credence ID has developed a low-cost, ... of offering enrollment and identification solutions to the ... was formed by experts from the mobile biometrics ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... researchers have found evidence for new genes involved in ... study, to be published in the next issue of ... gene variants in 4,000 volunteers. , Several ... Alzheimer?disease, the most interesting gene being ‘GALP?which could affect ...
... competitive with fossil fuels, there are significant potholes to ... has being addressed with the characterization of the genetic ... Department of Energy Joint Genome Institute (DOE JGI) and ... (FPL). The research, entailing the identification of numerous ...
... New evidence suggests that the risk of HIV transmission ... According to a study published in the April ... available online, early infection accounted for nearly half of ... province of Quebec, Canada. , Bluma Brenner, PhD, and ...
Cached Biology News:Study examines genetic risk factors for Alzheimer's disease 2Super-fermenting fungus genome sequenced 2Risk of HIV transmission highest early in infection 2
Sterile detoxified 10% bovine serum albumin (BSA) in Iscoves MDM. This BSA has been selected to support the optimal colony growth of human hematopoietic progenitor cells in methylcellulose-based medi...
... The TNT Coupled Reticulocyte Lysate Systems(a,b,c,d) ... in vitro translations: a single-tube, coupled ... greatly simplify the process and reduce ... vitro translation results. Standard rabbit reticulocyte ...
... ml per liter of urine will give a ... BMD dipstick. ,Certification: The Donors are of ... to be NEGATIVE for HbsAg, HCV, HIV-1 & ... FDA methods. THIS MATERIAL IS SOLD FOR IN-VITRO ...
... to the DH-2000, except that it uses a ... wavelength range and comes with a shutter (controlled ... 5 Hz) The DH-2000 Deuterium Tungsten ... deuterium and tungsten halogen light sources in a ...
Biology Products: